Also found in: Medical, Wikipedia.


A macrolide antibiotic, C38H69NO13, used to treat a variety of bacterial infections, especially of the respiratory tract.

[Probably c(h)la(mydia) (the causative agent of a type of pneumonia targeted by the drug) + alteration of (e)rythromycin.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n claritromicina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The title of Dr Sammia's paper was, 'Enhancement of Antimicrobial Activities and Dissolution Rate of Clarithromycin Nanoparticles.' It was co-authored by Muhammad Ashfaq.
pylori infection, consisting of a proton pump inhibitor prescribed with clarithromycin and either amoxicillin or metronidazole.
Summary: Clarithromycin may be taken by adult in dose 250-500 mg of immediate release tablets after meal twice daily.
pylori bacteria to the antibiotics commonly used in these therapies, primarily clarithromycin and metronidazole.
pylori isolates showed a 15% or higher pooled prevalence of primary and secondary resistance to clarithromycin, metronidazole, and levofloxacin in almost all World Health Organization (WHO) regions.
Objective: To assess the effectiveness of clarithromycin based standard triple therapy verses levofloxacin based first line therapy against Helicobacter pylori infection.
In the HEROES trial, patients were randomized to receive either triple therapy with omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg, all twice-daily (Omepramix[R], Ache Laboratorios Farmaceuticos SA, Sao Paulo, SP, Brazil) for 10 days (antibiotics group), or treatment with omeprazole 20 mg and placebo antibiotics, twice-daily (control group).
But a randomized, placebo-controlled clinical trial designed to determine the effects of a 14-day course of the macrolide clarithromycin (Biaxin) on patients with stable CAD reached a disturbing conclusion.
The bacterium Chlamydia pneumoniae is believed to contribute to coronary heart disease (CHD), since it is known to be present in plaques that clog arteries, and an antibiotic called clarithromycin (Biaxin[R]) has been shown to eradicate C.
THE FOOD AND DRUG Administration has added a new warning for an increased risk of death in patients with heart disease who have used clarithromycin (Biaxin), on the basis of results of a 10-year follow-up from the CLARICOR trial.